Search



Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Definition

The representation of a medicinal product as it is supplied in a package that contains within the package more than one type of clinical drug. 

Use Cases

The use cases supported by the Combination (Real) Packaged Clinical Drug concept Drug concept type are the same as those for the basic real packaged clinical drug , with the additional detail that administration that administration records may wish to identify which of the particular component clinical drugs were administered at any particular point in time of the administration event (using AIDC or similar).

Discussion

For abstract concepts, the combination packaged clinical drug , contains two or more different clinical drugs.

For real concepts, the combination real packaged real packaged clinical drug contains drug contains two or more different real clinical drugs.  The package is placed in the supply chain using a using a single name (which may be a trade or brand name) by a single supplier organisation, even if one or more of the component real clinical drugs is sourced from a different organisation; for .  For this reason, the 774158006 the 774158006 |Has product name| and 774159003 and 774159003 |Has supplier| attributes are optionally included.

A combination packaged clinical drug may also be called a "component product" or a "multi-component package" as the product itself is a package that contains more than one type of component element (clinical drug) within it; it .  It may also be known as or a "kit" or a "combination medicinal product". Occasionally a combination packaged clinical drug is may be known as a "compound product" , but this term risks being confused with products that are extemporaneously compounded by a pharmacist from a formula provided by the prescriber for an individual patient (sometimes also known as "magistral products").

Examples of combination packaged clinical drug include a package each containing:

  • A package containing clotrimazole cutaneous cream and one or more clotrimazole vaginal tablets for treatment of vaginal candidiasis
  • A package containing clotrimazole cutaneous cream and one or more fluconazole oral capsules for treatment of vaginal candidiasis
  • A package containing combinations of ethinylestradiol and levonorgestrel tablets in different strengths and which may also include inert tablets for oral contraception (note that in this example, the components are themselves multi-ingredient items)
  • A package containing amoxicillin, clarithromycin and lansoprazole for treatment of Helicobacter infection
  • A package containing a budesonide dispersible tablet and the vehicle to disperse it in , to make a rectal solution for treatment of colitis
  • A package containing rasburicase 1.5 mg powder for solution for injection and the diluent solution

This specification for national drug extensions recommends that a combination packaged clinical drug should should be represented only as packaged products (real packaged clinical drugs, and , if an abstract representation is required, as packaged clinical drugs), with their individual components represented as clinical drugs. For practical implementation of a national terminology, mechanisms such as reference sets may be used to include include combination packaged clinical drug with other classes of medicinal product (such as clinical drugs) to aid users in finding and selecting these products. 

...

Gliffy Diagram
macroId2aa7a840-f5c1-40c9-8baf-6db72049f8ab
displayNameCombination PCD
nameCombination PCD
pagePin1


Figure 3941: Diagram of options for a national extension describing combination real packaged clinical drugs

In some representations of combination packagescombination packages, and particularly in ISO 11615 in IDMP, a "combined dose form " concept is used in the name of the combination product (for example ", pessary and cream"). Although useful as a concept to describe the dose form using a single attribute and value, a combination dose form concept does not easily support knowing which component has which dose form. The model used here, whereby each clinical drug is described with its appropriate dose form and they are brought together into the packaged product containing the components, does not require the use of combination dose form concepts. 

For those combination packages that contain a diluent as an item in the package, national extensions may decide not to explicitly describe the diluent as a component , but merely to describe its presence in the text of the fully specified name for the real packaged medicinal product; alternatively, the national extension may author a "diluent" clinical drug concept and use that as one of the components of the combination product. If the constitution of the diluent is known (e.g., water for injections, 0.9% sodium chloride solution for injection), the clinical drug for the diluent can be explicitly described.  Dual chamber products containing the two components (where one is the diluent) in a single unit of presentation can be described as combination products if required.

Attributes

The following table describes the attributes for combination (real) packaged clinical drugs in a national extension.

The (real) packaged clinical drug class is related to the clinical drug class by a composition relationship relationship, and therefore the attribute "contains clinical drug" , the 

Concept
t774160008 |Contains clinical drug (attribute)|
is used to make the association between the packaged clinical drug and the clinical drugs it contains. 

Representation of packaged medicinal products should use Clinical Drugs that have presentation strength (either only, or in addition to, concentration strength) whenever possible in order to be able to accurately describe the number of presentation units present in the package. The exception will be is for continuous products such as semi-solid dose forms of creams, gels, etc. where strength pattern 3a is used (see international Editorial Guidelines International Medicinal Product Model). In all cases, the pack size and pack size unit should relate to the denominator unit of the strength.

Semantic tag

(packaged clinical drug)

OR

(real packaged clinical drug)

Definition status


Scg expression
900000000000073002 |Sufficiently defined concept definition status (core metadata concept)


Note: This can only be the case if extensions author concepts to represent real clinical drugs and/or product names and manufacturer / supplier organisations

Attribute: 

Scg expression


1142143009
|Count
of
clinical
drug
type (attribute)|


Range

  • INT (integer)

Cardinality

  • 1..1

Note

  • This attribute provides the number (count) of distinct clinical drug (concepts) present in the package.  For combination packages, this value should be greater than one

Attribute 

Attribute:
 
Scg expression
774158006
|Has
product
name (attribute)|



Scg expression
< 774167006 |Product name (product name)|


    • Extensions must author product name concepts within their extension using the root of 
      Concept
      t774167006 |Product name (product name)|
       from the Qualifier hierarchy

Cardinality

  • 0..1

Notes

  • The attribute value should represent the (authorised) product name; this may
(
  • or may not
)
  • be a trademarked name
,
  • and is often referred to as the "brand name" (see section below)
  • This attribute should only be valued in the rare circumstances when the product name for the combination product is known to be different from the product name of the component real clinical drugs

Attribute: 

Attribute:
scg-expression
774159003 |Has supplier (attribute)|

774159003

|Has

supplier (attribute)|




Scg expression
< 774164004 |Supplier (supplier)|


    • Extensions must author concepts to value supplier organisation information within their extension using the root of 
      Concept
      t774164004 |Supplier (supplier)|
       from the Qualifier hierarchy

Cardinality

  • 0..1

Notes

  • The attribute value should represent the holder of the marketing authorisation or authorisation for supply; this may or may not be the organisation responsible for the actual manufacture of the product (see section below)
  • This attribute should only be valued in the rare circumstances when the supplier for the combination product is known to be different from the supplier of component real clinical drugs
Role Group 
1..* for combination packaged clinical drugs

Attribute:

scg-expression

 

774160008

|Contains

clinical

drug (attribute)|




Scg expression
< 763158003 |Medicinal product (product)|


Cardinality

  • 1..1

Note

  • This attribute value represents the real clinical drug that is contained in the packaged product
    It is currently not possible to explicitly specify an expression to describe the range of (real) clinical drugs from a national extension to populate this attribute, since a range cannot currently recognise a set of concepts with a particular semantic tag - in this case "(real clinical drug)".  For the interim, the range is specified as the descendants of the root medicinal product concept: 763158003 |Medicinal product (product)|. 

Attribute:

 

  

1142142004 |Has pack size (attribute)|

scg-expression


1142142004

|Has

pack

size (attribute)|

Range

  • INT (integer)

Cardinality

  • 1..1

Note

  • This attribute represents the amount or quantity of the clinical drug in the role group present in the package; for presentation strength it is the number of countable units of presentation in the package; for concentration strength it is the mass or volume of the continuous dose form in the package

Attribute:

 scg-expression

774163005

|Has

pack

size

unit (attribute)|




Scg expression
<  767524001 |Unit of measure (qualifier value)|


Cardinality

  • 1..1

Note

  • This attribute value represents the unit of measure of the pack size in the role group;  for presentation strength it is the unit of presentation in the package; for concentration strength it is the unit of mass (e.g. gram) or volume (e.g. millilitre) of the continuous dose form in the package. 
    More specific range expressions such as "One of EITHER
732935002
  • <732935002 | Unit of presentation (unit of presentation)
- descendants only OR 258680008
  • OR <258680008 | Unit of mass (qualifier value)
- descendants only
  • OR
258769000
  • <258769000 | Unit of volume (qualifier value)
- descendants only
  • " are currently not supported, nor are rules based on the strength patterns that (for example) assert "if the clinical drug has a unit of presentation of 'tablet' then the Has_pack_size_unit will be valued as 'tablet'"
)
  • .


Example Diagrams

Example: combination packaged clinical drug: stated view followed by the inferred view

Image RemovedImage Added

Figure 4042: Example of a combination packaged clinical drug - stated view

Image RemovedImage Added

Figure 4143: Example of a combination packaged clinical drug - inferred view

Example: combination real packaged clinical drug: stated view followed by the inferred view

Image RemovedImage Added

Figure 4244: Example of a combination real packaged clinical drug - stated view

Image RemovedImage Added

Figure 4345: Example of a combination real packaged clinical drug - inferred view

IDMP Compatibility

Since the ISO the ISO 11615 standard treats all Packaged all Packaged Medicinal Products in the same manner , whether they are standard products or combination products, and because the associations between the manufactured item(s) present in the package are described using recursive relationships, the Combination Real Packaged Real Packaged Medicinal Product is equivalent to a Packaged a Packaged Medicinal Product identified by a PCID. As with the Real Packaged Real Packaged Medicinal Product. , the Combination Real Packaged Real Packaged Medicinal Product  Product is a representation a representation of the "real world product " authorised for sale and/or supply that exists for all jurisdictions and which is marketed into the supply chain for use, it is a concept that should form the 1:1 join between representation in the regulatory domain (IDMP) and representation in the clinical domain (SNOMED CT and national medicinal product terminologies) , even if some national medicinal product terminologies choose not to represent it.

...